Table 2.
Diabetes medication use at baseline and during follow-up
| Glycemic Control Therapy | Randomized to IS (%) | Randomized to IP (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n=922) | Year 1 (n=800) | Year 3 (n=813) | Year 5 (n=416) | Baseline (n=877) | Year 1 (n=569) | Year 3 (n=771) | Year 5 (n=417) | |
| Neither IS nor IP | 9.4 | 3.1 | 3.2 | 3.6 | 8.8 | 9.1 | 8.7 | 5.0 |
| IS only | 16.3 | 63.5 | 54.2 | 43.5 | 15.8 | 0.7 | 1.2 | 2.2 |
| IP only | 26.7 | 2.8 | 7.4 | 14.4 | 30.7 | 80.7 | 80.9 | 77.0 |
| Both IS and IP | 47.4 | 30.6 | 35.2 | 38.5 | 44.7 | 9.5 | 9.2 | 15.8 |
| IS drug class | ||||||||
| No TZD or metformin | 36.3 | 6.4 | 9.1 | 16.8 | 39.6 | 90.3 | 90.5 | 87.9 |
| TZD but no metformin | 7.4 | 6.9 | 12.2 | 10.7 | 5.6 | 0.5 | 0.9 | 1.0 |
| Metformin but no TZD | 44.0 | 23.5 | 26.5 | 30.0 | 43.4 | 7.4 | 6.8 | 9.2 |
| Both TZD and metformin | 12.4 | 63.3 | 52.2 | 42.4 | 11.4 | 1.8 | 1.8 | 1.9 |
| IP drug class | ||||||||
| No insulin or sulfonylurea | 26.2 | 67.0 | 59.3 | 51.7 | 25.6 | 12.1 | 11.3 | 8.5 |
| Sulfonylurea but no insulin | 49.7 | 11.8 | 13.7 | 14.4 | 47.1 | 37.4 | 29.0 | 23.0 |
| Insulin but no sulfonylurea | 17.2 | 19.0 | 23.3 | 29.0 | 20.7 | 32.7 | 35.4 | 43.3 |
| Both insulin and sulfonylurea | 6.9 | 2.3 | 3.7 | 4.9 | 6.6 | 17.8 | 24.3 | 25.2 |
| ACE-I or ARB | 76.7 | 90.0 | 91.6 | 89.3 | 77.6 | 91.2 | 92.7 | 92.3 |
IS, insulin-sensitizing drugs; IP, insulin-providing drugs; TZD, thiazolidinedione; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.